Skip to main content
Search

# pancreatic ductal adenocarcinoma

5 related articles

Subscribe to updates
  1. The FASEB Journal

    Integrating Metabolomics, Mendelian Randomization, and Machine Learning, a Study Flags Phenylalanine and Its Transporter SLC6A14 as Candidate Diagnostic and Therapeutic Targets in Pancreatic Cancer

    Integrating plasma metabolomics, Mendelian randomization, and machine learning, this study identified phenylalanine as causally associated with pancreatic cancer among 55 plasma metabolites (IVW OR = 1.641, 95% CI 1.052–2.562, p = 0.029), derived eight related differentially expressed genes, built a random forest diagnostic model from 113 combinations of 12 algorithms (training AUC 0.994; validation AUCs 0.918, 0.983, 0.923), used SHAP to rank SLC6A14 as the top feature, and combined single-cell sequencing, simulated gene knockout, molecular docking, and molecular dynamics to suggest genistein binds SLC6A14 stably, with RT-qPCR confirming high expression of the five model genes in a BxPC-3 versus HPDE6-C7 cell pair.

  2. The FASEB Journal

    Ellagic acid activates p38 and upregulates Keap1 to suppress Nrf2/HO-1, markedly enhancing RSL3-induced ferroptosis in pancreatic ductal adenocarcinoma

    In KRAS-mutant and KRAS wild-type pancreatic ductal adenocarcinoma cells (PANC-1, BxPC-3) and a PANC-1 subcutaneous xenograft model, this study shows that the natural polyphenol ellagic acid (EA) combined with the GPX4 inhibitor RSL3 synergistically reduces cell viability and suppresses tumor growth by activating p38 MAPK and upregulating Keap1 to inhibit the Nrf2/HO-1 antioxidant axis, amplifying ferroptotic hallmarks such as iron accumulation, lipid peroxidation, and GPX4 downregulation, with Fer-1 rescuing viability while apoptosis, necroptosis, and autophagy inhibitors do not.

  3. Microsoft Research introduces Quine: a multimodal biology world model that prioritized compounds driving tumor-state shifts in pancreatic cancer, narrowing candidates in a single weekend

    Microsoft Research introduces Quine, a research system combining a world model of biology trained jointly across modalities including sequence, structure, function, cellular state, and imaging with a harness connecting scientific tools, literature, the wet lab, and researchers; with the Broad Institute it used the system in pancreatic ductal adenocarcinoma (PDAC) to predict and prioritize thousands of compounds by their potential to shift tumor cells between therapeutically relevant states, wet-lab assays showed Quine's highest-ranked compounds produced the largest intended shifts, the whole process from narrowing the search space to prioritizing a handful of candidates took just one weekend, and the experiments also bore out the model's prediction of a distinct third phenotype.

  4. Decoding neuro-tumor interactions in pancreatic cancer: mechanisms, immunosuppressive networks and therapeutic opportunities

    This review systematically examines the molecular mechanisms of perineural invasion (PNI) in pancreatic ductal adenocarcinoma, proposes a unified four-stage model spanning mutual chemotaxis between tumors and nerves, adhesion and invasion at the tumor-nerve interface, extracellular matrix remodeling, and neural plasticity alterations, defines the perineural invasion microenvironment as a neuro-immune privileged sanctuary, and summarizes therapeutic strategies targeting the neuro-immune-tumor axis, ongoing clinical trials, and the applications of multi-omics and artificial intelligence in PNI diagnosis, mechanistic discovery, and therapeutic optimization.

  5. Spatial Configuration of Residual Pancreatic Cancer Is Associated with Recurrence Risk

    In 203 patients with pancreatic ductal adenocarcinoma who received neoadjuvant therapy and curative-intent resection and were restricted to minor pathologic response, an AI-enabled pipeline segmented cancer and stroma from routine H&E whole-slide images and quantified spatial composition and configuration, finding that a fragmented, interface-rich tumor-stroma ecology was independently associated with shorter disease-free survival; two spatial risk models (cancer mean shape index plus stromal shape index variability, adjusted HR 1.71, P = 0.003; mean stromal patch area plus edge density, adjusted HR 2.19, P = 0.

You’re all caught up